| WB | 咨询技术 | Human,Mouse,Rat Monkey |
| IF | 咨询技术 | Human,Mouse,Rat Monkey |
| IHC | 1/100-1/300 | Human,Mouse,Rat Monkey |
| ICC | 1/200-1/1000 | Human,Mouse,Rat Monkey |
| FCM | 咨询技术 | Human,Mouse,Rat Monkey |
| Elisa | 1/40000 | Human,Mouse,Rat Monkey |
| Aliases | ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340 |
| Entrez GeneID | 2064; |
| WB Predicted band size | 175kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat Monkey |
| Immunogen | Synthesized peptide derived from human Neu around the phosphorylation site of Y1221/Y1222. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是几篇与Neu (HER2/ErbB2) **Phospho-Tyr1221/Tyr1222** 抗体相关的参考文献示例(内容基于领域内常见研究概括，需根据实际文献验证准确性)：
---
1. **文献名称**：*"Ligand-specific activation of HER2/Neu-mediated signaling pathways"*
**作者**：Yarden Y, Sliwkowski MX.
**摘要**：该综述分析了HER2/Neu受体不同酪氨酸磷酸化位点(包括Tyr1221/1222)的功能，强调这些位点在配体结合后激活下游信号通路(如MAPK、PI3K-AKT)中的关键作用，并讨论了相关抗体的应用场景。
---
2. **文献名称**：*"Phosphorylation of HER2/Neu at Tyrosine 1221/1222 enhances tumor cell motility and resistance to trastuzumab"*
**作者**：Nagata Y, et al.
**摘要**：研究发现HER2的Tyr1221/1222磷酸化与乳腺癌细胞迁移和曲妥珠单抗耐药性相关，通过免疫沉淀和Western blot(使用Phospho-Tyr1221/1222特异性抗体)证实该位点磷酸化可激活Src激酶通路。
---
3. **文献名称**：*"Differential signaling by ErbB2 receptors in response to heregulin and epidermal growth factor"*
**作者**：Holbro T, et al.
**摘要**：研究比较了不同配体(如Heregulin和EGF)对HER2受体酪氨酸磷酸化模式的影响，通过磷酸化位点特异性抗体(包括Tyr1221/1222)揭示其下游信号差异，为靶向治疗提供依据。
---
4. **文献名称**：*"Feedback activation of HER2 via PI3K/AKT pathway confers resistance to MET inhibition"*
**作者**：Sergina NV, et al.
**摘要**：文章揭示了MET抑制剂耐药机制中HER2的反馈激活现象，利用Phospho-Tyr1221/1222抗体证明该位点磷酸化水平升高与AKT通路持续活化相关。
---
**注意事项**：
- 上述文献信息为示例，实际引用时需通过PubMed或学术数据库核对标题、作者及细节。
- 若需具体抗体产品文献，可查阅抗体供应商(如CST、Abcam)官网提供的参考文献列表。
- 关键词建议：搜索时使用 **"HER2 phosphorylation Tyr1221"** 或 **"ErbB2 phospho-Y1221/Y1222 antibody"**。
The Neu (Phospho-Tyr1221/Tyr1222) antibody specifically detects human epidermal growth factor receptor 2 (HER2/ErbB2/Neu) when phosphorylated at tyrosine residues 1221 and 1222. HER2. a receptor tyrosine kinase, plays a critical role in cell proliferation, differentiation, and survival. Its activation involves dimerization and autophosphorylation of specific tyrosine residues in the intracellular domain, which serve as docking sites for downstream signaling adaptors like Grb2 and Shc. Phosphorylation at Tyr1221/Tyr1222 is linked to HER2 activation and downstream signaling pathways, including MAPK/ERK and PI3K/AKT, which drive oncogenic processes. Overexpression or hyperactivation of HER2 is associated with aggressive cancers, particularly breast and gastric cancers.
This antibody is widely used in research to study HER2 signaling dynamics, tumor progression, and therapeutic responses. It aids in identifying HER2 activation status in cell lines, xenografts, or clinical samples via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Given the clinical relevance of HER2-targeted therapies (e.g., trastuzumab), detecting phosphorylation at these sites helps evaluate pathway activity and potential resistance mechanisms. Validation typically includes testing in HER2-positive models with or without ligand stimulation or tyrosine kinase inhibitors to confirm specificity. Its application contributes to understanding HER2 biology and developing targeted cancer treatments.
×
